# Twinstrand Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/twinstrand-biosciences

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.twinstrandbio.com
- Total disclosed funding: $66M
- Latest round: Series B (Apr 30, 2021)
- Investors on record: 7

## About

Twinstrand Biosciences develops advanced genomic sequencing technologies, with a focus on TwinStrand Duplex Sequencing®, which significantly improves sequencing accuracy for various applications in genomics and precision medicine.Founded in 2015 and headquartered in Seattle, US, Twinstrand Biosciences specializes in genomic sequencing technologies. The company has completed 2 funding deals, with the most recent being a Series B round on April 30, 2021, in which it raised USD 50.00 mn, led by Section 32, with participation from other notable investors. CEO Jesse Salk, who co-founded the company, has been involved in the genomics and biotechnology sectors prior to this venture.Twinstrand Biosciences specializes in advanced genomic sequencing technologies, primarily focusing on its flagship product, TwinStrand Duplex Sequencing®. This technology enhances sequencing accuracy by reducing error rates from 1-in-100 to 1-in-10 million. It independently tracks both strands of DNA molecules, allowing researchers to detect low-frequency variants often undetectable by standard next-generation sequencing (NGS) methods. Their solutions are targeted at various applications, including measurable residual disease monitoring in acute myeloid leukemia, mutation signature analysis, and cellular immunotherapy assessment, catering to research institutions, pharmaceutical companies, and regulatory organizations across North America, Europe, and parts of Asia.Twinstrand Biosciences generates revenue through the sale of its Duplex Sequencing technology and associated research kits, which are marketed for research use only. Transactions mainly occur via direct sales to research institutions and collaborations with pharmaceutical companies seeking tailored genomic research solutions. Their pricing structure reflects the advanced capabilities of their technologies, and clients often engage in multi-year agreements or one-time purchases of research kits tailored to their specifications. Twinstrand emphasizes building long-term relationships with clients, ensuring ongoing support and updates as technology evolves.Following the Series B financing round in April 2021, Twinstrand Biosciences plans to leverage the USD 50.00 mn raised to expand the adoption of its Duplex Sequencing technology in applications requiring high sensitivity and accuracy. The company aims to develop new products designed for emerging genomic applications while exploring opportunities for expansion into new markets, particularly in Europe and Asia, by the end of 2023.

## Funding rounds

- Series B, Apr 30, 2021, $50M — Alexandria Venture Investments, Madrona Venture Group, Ridgeback Capital Management, Section 32, Janus Henderson Investors, Soleus Capital
- Series A, Jan 7, 2020, $16M — Alexandria Venture Investments, Madrona Venture Group, Ridgeback Capital Management, Sahsen Foundation

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B
- Madrona Venture Group (https://capitalatlas.ai/funds/madrona-venture-group) — Series A, Series B
- Ridgeback Capital Management — Series A, Series B
- Sahsen Foundation — Series A
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series B
- Janus Henderson Investors — Series B
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series B